CNP/cGMP signaling counteracts metabolic reprogramming in pulmonary arterial hypertension pericytes by reducing HIF1α, GLUT-1, and CAD activity, thereby normalizing glycolysis and pyrimidine synthesis and limiting hyperproliferation, highlighting its therapeutic potential. This evidence concerns the gene CAD and pulmonary arterial hypertension.